Skip to main content

Efficacy of High-Dose Vitamin D Supplementation in the Critically Ill Patients

Buy Article:

$68.00 + tax (Refund Policy)

Vitamin D deficiency and its adverse skeletal sequelae are well recognized in the general population. Recent observation of high prevalence of low vitamin D states and their associations with worse clinical outcomes in critically ill populations have sparked interest in the role of supplementation for these patients. High-dose vitamin D efficaciously increases serum levels, but its impact on clinical outcome has not been examined. This article will review results from observational studies on prevalence and outcomes of hypovitaminosis D in critically ill patients, as well as caveats of vitamin D interventional trials. Improved understanding of vitamin D metabolism in critical illness will clarify the therapeutic potential of this pleiotropic hormone and facilitate implementation of cost-effective clinical trials.

Keywords: Critical illness; Vitamin D; critically ill; high-dose supplementation; hypovitaminosis D

Document Type: Research Article

Publication date: 01 August 2013

More about this publication?
  • Inflammation & Allergy - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in inflammation and allergy e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in inflammation and allergy. As the discovery, identification, characterization and validation of novel human drug targets for anti-inflammation and allergy drug discovery continues to grow, this journal has become essential reading for all pharmaceutical scientists involved in drug discovery and development.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content